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Albrecht Fleckenstein: Father of Calcium Antagonism
LOUIS J. ACIERNO, M.D., F.A.C.C., L. TIMOTHY WORRELL, M.P.H., R.R.T.
University of Central Florida, College of Health and Public Affairs, Orlando, Florida, USA
Verapamil, the original calcium-channel-blocking agent,
along with its congeners, has become a markedly important
component in the current management of hypertension, isch-
emic heart disease, and certain cardiac arrhythmias—and we
owe it all to Albrecht Fleckenstein (Fig. 1), described by his
peers in the International Society for Heart Research as “an
imaginative scientist, a remarkable human being and a color-
ful personality.”1
Albrecht Fleckenstein was born in Aschaffenburg, Ger-
many, in 1917 and died in Freiburg in 1992. He received his
medical training in Würzburg and Vienna. His scientific career
began in the Pharmacology Department of Würzburg Univer-
sity. World War II interrupted his career; during this time he
was a prisoner of war of the American army for 2 years. With
the cessation of hostilities, Fleckenstein was able to resume his
scientific interests under Professor Eichholtz at the Depart-
ment of Pharmacology at the University of Heidelberg.2 Dur-
ing this time he completed his “Habilitation” in pharmacology
and toxicology. This was in 1947 and he was only 30 years old. 
Initially Fleckenstein’s research was concentrated on the
physiologic changes associated with pain and muscle contrac-
tion. As time went on, his attention shifted increasingly to met-
abolic and electrophysiologic changes of the heart.2 In 1951,
he became one of the first post-war German scientists to be of-
fered an exchange appointment. His was at the Department of
Pharmacology at Oxford University under Professor Burn.
While working with Professor Burn at Oxford, he analyzed
the mechanism of the potentiation and inhibition of the sym-
pathomimetics by cocaine, and it was at this time that he intro-
duced the term “neurosympathomimetics.” Several years later,
he introduced another term, “cathelectrotonic,” which empha-
sized the importance of cation movements through the cell
membrane for many physiologic processes. This term ap-
peared in a monograph entitled “the potassium-sodium ex-
change as energy principle in muscle and nerve.”3 In 1956, he
was appointed Chair of Physiology at Albert-Ludwigs-Uni-
versität in Freiburg im Breisgau. This was to become his intel-
lectual home for the rest of his life despite invitations to move
to both Basel and Graz. During his first year at Freiburg, his re-
search concentrated on the relationship between energy-rich
phosphates, contractility of cardiac muscle, and metabolic as-
pects of the excitation-contraction coupling. While he was en-
gaged in this work he became interested in the interaction of
cations with the contractile processes of cardiac muscle. This
led him to report, in 1964, that prenylamine and verapamil
have the same inhibitory action on the excitation-contraction
coupling as calcium withdrawal from the Ringer’s solution.
He continued to use verapamil, originally known as iprovera-
tril,5 as a tool in the initial pharmacologic studies that led him
toward the discovery of the “calcium antagonists” in 1968–
1969. It was at this time that Dr. H. G. Kroneberg gave
Fleckenstein a sample of nifedipine with the suggestion that it
could also be a calcium antagonist.3 Fleckenstein confirmed
that nifedipine was indeed not only a calcium antagonist, but
also one of the most active ones he “ever had in his hands.”3
Twenty more years of intensive pharmacologic work stimulat-
ed extensive theoretical and clinical research and development
with important therapeutic consequences regarding calcium
antagonists. In time, with verapamil leading the group, these
antagonists were to become a new group of drugs for the treat-
ment of angina pectoris, hypertension, and certain types of
atrial arrhythmias.3
Fleckenstein also discovered the relationship of calcium to
necrotization of cardiac muscle by isoproterenol. He discov-
ered that blocking high-energy phosphates, resulting from ex-
cessive activation of calcium-dependent ATPase, prevented
subsequent necrosis of the heart muscle. All this was attrib-
utable to the action of calcium antagonists.1
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Fleckenstein presented himself as a formidable figure with
his booming voice and large physical presence. Despite this,
he revealed himself as a generous, kind, and committed indi-
vidual interested in the contributions of others and always will-
ing to debate other points of view.6 Fleckenstein was described
by Bing1 as an individual who disliked pretense and whose ap-
proach to science was original and refreshing because he went
directly to the point. Bing goes on to describe an incident at the
international meeting of the International Society for Heart
Research in Freiburg, Germany, in 1973, wherein Flecken-
stein, with apparent equanimity, silenced a group of rebel stu-
dents who were about to disrupt the meeting for a banal rea-
son. The students wanted to complain about the visiting
Americans who, during a visit to the local museum, had de-
posited cigarette ashes into containers which the medieval
sculptor had intended for a different purpose.1 At another time,
Nayler4 describes an argument he had with Fleckenstein over
the appropriate terminology for the drugs that Fleckenstein
had labeled calcium antagonists. Some pharmacologists in-
cluding Nayler believed a more appropriate term would be cal-
cium-channel blocker. Again Fleckenstein “won the day” by
saying with his usual honesty and simplicity that the term cal-
cium antagonist was more appropriate because he thought of
that designation.4
Fleckenstein was a prolific author, with more than 800 ref-
erences documenting his intensive scientific activity. He re-
ceived numerous international and national honors, which
included honorary doctoral degrees from the universities of
Munich, Heidelberg, Basel, Limburg (the Netherlands), and
the National University of La Plata (Argentina). He also re-
ceived the Albert Einstein World Award of Sciences, the
Distinguished Investigator Award of the American Society
of Clinical Pharmacology, the Award for Outstanding Cardi-
ological Research of the International Society for Heart Re-
search, and the American Society for Pharmacology and Ex-
perimental Therapeutics (ASPET) Award for Outstanding
Basic Pharmacological Investigations. He was also an hon-
orary member of national and international physiologic and
cardiological societies too numerous to mention.3
Albrecht Fleckenstein was fortunate in sharing his profes-
sional and private life with his wife, Dr. Gisa Fleckenstein-
Grün, who was also Professor of Physiology at the same uni-
versity. Survived by his wife and three daughters, he was buried
in St. Ulrich, a village in one of the valleys of the Black Forest.3
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